NatWest Group plc Reduces Stock Holdings in Gilead Sciences, Inc. $GILD

NatWest Group plc lowered its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 28.3% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 88,555 shares of the biopharmaceutical company’s stock after selling 34,911 shares during the quarter. Gilead Sciences makes up approximately 2.4% of NatWest Group plc’s holdings, making the stock its 18th biggest position. NatWest Group plc’s holdings in Gilead Sciences were worth $9,830,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in the business. GoalVest Advisory LLC grew its position in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 227 shares during the period. Activest Wealth Management boosted its stake in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares during the last quarter. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $27,000. Howard Hughes Medical Institute bought a new stake in shares of Gilead Sciences during the 2nd quarter valued at $30,000. Finally, Putney Financial Group LLC increased its stake in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 94 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on GILD shares. Argus lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. JPMorgan Chase & Co. lifted their price objective on Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a research report on Friday, October 31st. Daiwa Capital Markets boosted their price objective on Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. TD Cowen increased their target price on shares of Gilead Sciences from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday, October 23rd. Finally, UBS Group raised shares of Gilead Sciences to a “hold” rating in a report on Thursday, December 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Gilead Sciences currently has an average rating of “Moderate Buy” and an average target price of $131.54.

Gilead Sciences Stock Up 2.2%

Shares of GILD opened at $121.36 on Thursday. The business’s 50 day moving average is $122.12 and its 200 day moving average is $115.97. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a 12-month low of $88.57 and a 12-month high of $128.70. The company has a market capitalization of $150.57 billion, a PE ratio of 18.82, a price-to-earnings-growth ratio of 0.66 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The business had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period in the prior year, the company posted $2.02 EPS. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 30th. Investors of record on Monday, December 15th will be paid a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Monday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Insider Buying and Selling

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the business’s stock in a transaction on Friday, November 28th. The shares were sold at an average price of $125.08, for a total value of $625,400.00. Following the sale, the director owned 8,920 shares in the company, valued at $1,115,713.60. The trade was a 35.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Friday, November 28th. The shares were sold at an average price of $126.54, for a total transaction of $1,265,400.00. Following the transaction, the chief executive officer directly owned 571,203 shares of the company’s stock, valued at $72,280,027.62. This trade represents a 1.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 136,257 shares of company stock worth $16,723,492 in the last 90 days. 0.27% of the stock is owned by company insiders.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.